IRONWOOD PHARMACEUTICALS INC Operating Income

Quick Answer

IRONWOOD PHARMACEUTICALS INC reported Operating Income of $98.50 million for fiscal year 2025.

IRONWOOD PHARMACEUTICALS INC Operating Income — Annual History

Fiscal Year Operating Income YoY Change
2025 $98.50M +5.8%
2024 $93.12M +109.8%
2023 -$945.43M -477.7%
2022 $250.34M +7.8%
2021 $232.26M +62.5%
2020 $142.94M +19.0%
2019 $120.12M +179.7%
2018 -$150.67M -880.7%
2017 -$15.36M +70.4%
2016 -$51.87M +49.2%
2015 -$102.09M +39.7%
2014 -$169.37M +32.8%
2013 -$252.00M -246.3%
2012 -$72.76M -10.0%
2011 -$66.14M -8.8%
2010 -$60.77M +0.1%
2009 -$60.82M

Quarterly Operating Income

Quarter Ending Operating Income YoY QoQ
September 30, 2025 $75.48M +194.4% +66.6%
June 30, 2025 $45.32M +81.5% +255.7%
March 31, 2025 -$29.11M -364.1% -213.5%
September 30, 2024 $25.64M -35.9% +2.6%
June 30, 2024 $24.98M +102.3% +126.7%
March 31, 2024 $11.02M -81.7% -72.5%
September 30, 2023 $40.02M -41.5% +103.7%
June 30, 2023 -$1.08B -2046.2% -1902.3%
  • IRONWOOD PHARMACEUTICALS INC showed an increase of +5.8% in Operating Income compared to the prior fiscal year.
  • Over the 2009–2025 period, IRONWOOD PHARMACEUTICALS INC’s operating income has grown by 262.0% (from -$60.82 million to $98.50 million).
  • The most recent figure is from IRONWOOD PHARMACEUTICALS INC’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 26, 2026.
  • All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.

Last verified:

Leave a Comment